PeptiDream and Ipsen Enter Drug Discovery Collaboration
News Apr 11, 2013
The research collaboration will combine PeptiDream’s proprietary peptide library with Ipsen’s expertise in peptide drug discovery and pharmaceutical R&D. The financial terms of the agreement are not disclosed. In exchange for world-wide rights to the therapeutic peptides resulting from the collaboration, Ipsen will make an upfront payment to PeptiDream and pay R&D and commercialization costs. PeptiDream will receive royalties on worldwide sales; or have the right to opt-in at predefined stages to support Japan development costs for royalty free commercial rights in that territory. In the latter circumstance, PeptiDream would also forego royalty income for ex-Japan sales.
“Our partnership with Ipsen to discover novel therapeutic peptides for serious debilitating disease reinforces the status of PeptiDream as a major force in therapeutic peptide discovery in the pharmaceutical industry worldwide,” said Patrick Reid, Ph.D., Chief Scientific Officer and Head of PeptiDream's discovery programs.
“Ipsen and PeptiDream now enter into a research collaboration to discover novel highly-selective peptides targeting specific serious disease using the synergies of skills and competencies between both companies. We believe the Ipsen – PeptiDream agreement implements our philosophy to apply innovation for future patient care,” stated Dr. Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen.
Molecular Mechanism That Enable Neuronal Connections to Change With Development DiscoveredNews
Researchers from King's College London have discovered a molecular mechanism that enables neuronal connections to change through experience, thus fuelling learning and memory formation.READ MORE
Thermo, SRI International Collaborate to Enhance Small Molecule ResearchNews
Thermo set to collaborate with SRI International to combine results of Orbitrap LC/MS experiments with organism-specific metabolic pathway and genome data to improve small molecule research and analysis.READ MORE
Metabolomic Analysis Reveals Underlying Cause of Weaker Bones in Diabetic MiceNews
Investigators report that hyperglycemic mice have a 24-fold higher accumulation of succinate in the metabolic pathways of their bone marrow stromal cells.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018